PPAR Agonists and Metabolic Syndrome: An Established Role?

Area of Science:

• Endocrinology and Metabolism
• Pharmacology

Background:

• Metabolic syndrome (MetS) involves complex dysregulation of lipids, glucose, and adiposity.
• Peroxisome proliferator-activated receptors (PPARs) are key regulators of metabolic processes.
• Existing therapies target lipoproteins, blood pressure, or anthropometrics with varying efficacy.

Purpose of the Study:

• To review the therapeutic potential of PPAR agonists in managing MetS.
• To explore the distinct roles of PPAR-α, PPAR-γ, and dual PPAR-α/δ agonists.
• To highlight the application of PPARs in treating non-alcoholic fatty liver disease (NAFLD).

Main Methods:

• Review of scientific literature on PPAR agonists and their clinical applications.
• Analysis of the mechanisms of action for different PPAR subtypes.
• Evaluation of efficacy and safety profiles of PPAR-targeting drugs.

Main Results:

• PPAR-α agonists (fibrates, omega-3s) effectively lower triglycerides (TGs) and raise HDL-C.
• PPAR-γ agonists (glitazones) primarily improve glucose control.
• Novel dual PPAR-α/δ agonists offer combined TG-lowering, HDL-C-raising, and insulin-sensitizing effects.
• PPAR agonists show potential for treating NAFLD associated with MetS.

Conclusions:

• The PPAR system provides a promising therapeutic avenue for atherogenic dyslipidemias in MetS.
• Dual PPAR agonists represent a significant advancement in managing multiple metabolic derangements.
• Potential adverse events including creatinine increase, gallstones, and myopathy require careful monitoring.